

August 1, 2017

1 Page

Dear Colleague,

The purpose of this letter is to notify you of updates at the Molecular Otolaryngology & Renal Research Laboratories (MORL), which will go into effect on September 1, 2017.

### **Changes to the Genetic Renal Panel**

In our continuing mission to provide the most comprehensive resource for your patients with TMAs and complement-mediated renal diseases, we have expanded our clinical MLPA (Multiple Ligation Probe Amplification) to screen copy number variants over the complete complement Factor H-related region as part of our Genetic Renal Panel. Previously, we only screened the complete region if initial analysis of the *CFHR3-CFHR1* indicated further inquiry was necessary. Now we will screen the whole region (*CFH-CFHR5*) on *every patient...every time...* with no increase in price or turnaround time of the Genetic Renal Panel.

### **Changes to the Functional Testing**

**ADAMTS-13 Testing:** MORL has restructured our ADAMTS-13 testing menu to offer a wider range of options. You can order ADAMTS-13 activity only or ADAMTS-13 activity with reflex to inhibitor. As usual, we will report ADAMTS-13 activity within 1 business day. If reflexed (when ADAMTS-13 activity is <25%), the inhibitor result will be reported within 1 business day after you receive your patient's activity report. You can also order ADAMTS-13 inhibitor alone only if your patient has been previously tested for inhibitor and the result was positive.


**Classical Pathway Testing:** MORL has changed our methodology of evaluating the classical pathway (CP). Traditional hemolytic-based CH50 is performed using antibody-sensitized sheep erythrocytes as the activator of the CP. The amount required to give 50% hemolysis is determined spectrophotometrically. Our new ELISA-based method (**CH50eq**) provides a direct measure of the CP activity in serum by quantifying the amount of newly formed terminal complement complex under standard conditions. This method is more sensitive than the traditional hemolytic-based CH50 assay.

### **Billing and New Requisition Form**

For the Genetic Renal Panel, and any panel with the updated CH50eq test, there will be no change in CPT codes or pricing. There are no changes in the CPT codes for ADAMTS-13 Activity or Inhibitor. **Our updated test menu and requisition form will be available on our website (<https://morl.lab.uiowa.edu>) on September 1<sup>st</sup>.**

If you have any questions please do not hesitate to contact me or the MORL team (Amy Weaver at tel: 319 335-6623 or [amy-weaver@uiowa.edu](mailto:amy-weaver@uiowa.edu); Jori Hendon at tel:319 335-6653 or [jori-hendon@uiowa.edu](mailto:jori-hendon@uiowa.edu) ).

With kind regards,



Richard JH Smith, MD  
Director - Molecular Otolaryngology and Renal Research Laboratories,  
and The Iowa Institute of Human Genetics  
Professor of Internal Medicine and Pediatrics (Divisions of Nephrology), Otolaryngology,  
Molecular Physiology & Biophysics  
Sterba Hearing Research Professor and Vice Chair - Department of Otolaryngology  
[richard-smith@uiowa.edu](mailto:richard-smith@uiowa.edu)